Motif Bio (NASDAQ:MTFB) Upgraded to “Sell” by ValuEngine

Motif Bio (NASDAQ:MTFB) was upgraded by investment analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued on Friday, February 2nd.

Several other equities analysts have also recently issued reports on the company. WBB Securities assumed coverage on Motif Bio in a research report on Friday, December 29th. They set a “sell” rating and a $7.00 target price on the stock. Seaport Global Securities reiterated a “buy” rating on shares of Motif Bio in a research report on Friday, December 22nd. Finally, HC Wainwright set a $32.00 price target on Motif Bio and gave the stock a “buy” rating in a report on Wednesday, October 11th. Two analysts have rated the stock with a sell rating and three have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $21.33.

Motif Bio (NASDAQ:MTFB) traded down $0.18 during midday trading on Friday, reaching $10.12. The company’s stock had a trading volume of 3,700 shares, compared to its average volume of 3,641. Motif Bio has a 52 week low of $5.80 and a 52 week high of $13.75.

COPYRIGHT VIOLATION NOTICE: “Motif Bio (NASDAQ:MTFB) Upgraded to “Sell” by ValuEngine” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/13/motif-bio-mtfb-upgraded-by-valuengine-to-sell.html.

Motif Bio Company Profile

Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is Iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Motif Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif Bio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply